Structural and binding studies of cyclin-dependent kinase 2 with NU6140 inhibitor

Chem Biol Drug Des. 2021 Nov;98(5):857-868. doi: 10.1111/cbdd.13941. Epub 2021 Sep 5.

Abstract

Cyclin-dependent kinase 2 (CDK2) is an established target protein for therapeutic intervention in various diseases, including cancer. Reported inhibitors of CDK2 target the ATP-binding pocket to inhibit the kinase activity. Many small molecule CDK2 inhibitors have been discovered, and their crystal structure with CDK2 or CDK2-cyclin A complex has been published. NU6140 is a CDK2 inhibitor with moderate potency and selectivity. Herein, we report the cocrystal structure determination of NU6140 in complex with CDK2 and confirmation of the binding using various biophysical methods. Our data show that NU6140 binds to CDK2 with a Kd of 800 nM as determined by SPR and stabilizes the protein against thermal denaturation (ΔTm -5°C). The cocrystal structure determined in our study shows that NU6140 binds in the ATP-binding pocket as expected for this class of compounds and interacts with Leu83 and Glu81 with regular hydrogen bonds and with Asp145 via water-mediated H-bond. Based on these data, we propose structural modifications of NU6140 to introduce new interactions with CDK2 that can improve its potency while retaining the selectivity.

Keywords: CDK2; NU6140; X-ray crystallography; crystal structure; surface plasmon resonance.

MeSH terms

  • A549 Cells
  • Adenosine Triphosphate / chemistry
  • Amino Acid Sequence
  • Binding Sites
  • Cell Survival / drug effects
  • Crystallography, X-Ray
  • Cyclin-Dependent Kinase 2 / antagonists & inhibitors*
  • Humans
  • Hydrogen Bonding
  • Protein Binding
  • Protein Conformation
  • Protein Kinase Inhibitors / chemistry*
  • Purines / chemistry*
  • Structure-Activity Relationship
  • Thermodynamics

Substances

  • 4-(6-cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide
  • Protein Kinase Inhibitors
  • Purines
  • Adenosine Triphosphate
  • Cyclin-Dependent Kinase 2